{'fraction_non_alphanumeric': 0.027237354085603113, 'fraction_numerical': 0.007782101167315175, 'mean_word_length': 5.906040268456376, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE)

The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin gene superfamily, encoded within the major histocompatability complex class III region. Its multiple ligands include the high mobility group box 1 chromatin binding protein, HMGB1. Recently we reported that RAGE-HMGB1 critically regulates autophagy and apoptosis in pancreatic cancer cells in vivo and in vitro in response to chemotherapy. RAGE inhibits apoptosis (“programmed cell death”) by a p53 transcription-independent pathway during the response to chemotherapeutic agents. RAGE sustains autophagy (“programmed cell survival”) associated with decreased phosphorylation of the mammalian target of rapamycin (mTOR) and increased Beclin 1-Vps34 interaction. These findings provide insight into how autophagy- and apoptosis-crossregulatory molecules interact in response to cellular stress including tumor therapy.